Ballentine Partners LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 82.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 63,731 shares of the biopharmaceutical company’s stock after acquiring an additional 28,850 shares during the period. Ballentine Partners LLC’s holdings in Pfizer were worth $2,108,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. DE Burlo Group Inc. increased its holdings in shares of Pfizer by 65.4% in the 2nd quarter. DE Burlo Group Inc. now owns 6,957 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 2,750 shares during the last quarter. Highstreet Asset Management Inc. boosted its stake in shares of Pfizer by 225.4% during the 2nd quarter. Highstreet Asset Management Inc. now owns 318,230 shares of the biopharmaceutical company’s stock worth $10,694,000 after purchasing an additional 220,431 shares during the period. Everett Harris & Co. CA boosted its stake in shares of Pfizer by 0.6% during the 2nd quarter. Everett Harris & Co. CA now owns 67,575 shares of the biopharmaceutical company’s stock worth $2,270,000 after purchasing an additional 416 shares during the period. Camden National Bank purchased a new position in shares of Pfizer during the 2nd quarter worth about $234,000. Finally, Allegis Investment Advisors LLC boosted its stake in shares of Pfizer by 7.1% during the 2nd quarter. Allegis Investment Advisors LLC now owns 67,799 shares of the biopharmaceutical company’s stock worth $2,277,000 after purchasing an additional 4,512 shares during the period. Institutional investors own 69.89% of the company’s stock.
PFE has been the subject of several research reports. UBS set a $40.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Tuesday, October 3rd. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective for the company. in a research report on Wednesday, September 13th. Finally, Cowen set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $38.77.
Pfizer Inc. (NYSE:PFE) traded down $0.06 during mid-day trading on Thursday, hitting $35.50. 15,807,773 shares of the stock traded hands, compared to its average volume of 19,960,639. Pfizer Inc. has a fifty-two week low of $30.51 and a fifty-two week high of $36.78. The stock has a market cap of $212,380.00, a P/E ratio of 14.25, a P/E/G ratio of 2.51 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the prior year, the firm posted $0.61 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. equities analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.61%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 79.01%.
In other news, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders have sold 60,280 shares of company stock worth $2,118,988 over the last three months. 0.06% of the stock is currently owned by insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.